Clinical Trial

Millions suffer from chronic facial pain with few options. A new FDA-cleared device from Curonix offers a permanent, evidence-based solution.

A landmark Nature Medicine publication for OrsoBio's TLC-2716 offers new hope for millions suffering from severe lipid and liver disorders.

Results in Nature Medicine reveal an immunotherapy that may stop cancer before it starts in high-risk Lynch Syndrome carriers, heralding a new era of prevention.

Basketball legends and the Prostate Cancer Foundation unite in a new initiative to fight late detection, urging men of color to prioritize life-saving screenings.

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

Flashpoint Therapeutics appoints an FDA-approved drug developer as CSO, a strategic move to accelerate its groundbreaking structural nanomedicine platform.

A new celebrity-backed eye drop promises freedom from reading glasses. We look at the science, the competition, and what it means for 128M Americans.

Adial Pharmaceuticals files a key patent to protect its personalized Alcohol Use Disorder drug, AD04, until 2045, signaling a new era for addiction medicine.

With major funding and a seasoned CEO, Caldera Therapeutics is advancing a first-in-class bispecific antibody into the clinic for inflammatory bowel disease.

A new partnership aims to bring a revolutionary, disease-modifying stem cell therapy for knee osteoarthritis to millions of patients in Greater China.

New data shows clients now prioritize healthy aging over beach bodies, reshaping the fitness industry from training goals to technology and medical collaboration.

Propanc Biopharma is taking a 100-year-old cancer treatment concept into modern human trials, targeting advanced tumors and expanding into fibrosis.

Kye Pharma brings SLENYTO®, a first-of-its-kind prescription sleep aid, to Canada, offering relief to children with ASD and SMS and their families.

MedTech firm Lifeward is acquiring Oramed's oral insulin tech, despite a past trial failure, in a high-stakes deal that could redefine both companies.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

FDA clears a novel two-part immunotherapy that paints solid tumors with a synthetic target, unleashing a powerful CAR T-cell attack in a new clinical trial.

TriSalus Life Sciences reports record 53% annual revenue growth, but a closer look reveals a complex financial picture for the oncology innovator.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

As part of a $23B US investment, Novartis will build a cutting-edge facility in Winter Park, cementing Florida’s role in advanced cancer treatment.